Vimpat Meets Endpoint in Trial

Belgian drugmaker UCB reported that Vimpat, a treatment for diabetic neuropathic pain, reduced average daily pain scores in a Phase III trial.

The 551-patient, randomized, double-blind, placebo-controlled study evaluated Vimpat (lacosamide) 400 mg in two titration models — a standard titration regimen in which patients reached the target dose at day 22 and a fast regimen in which patients reached the target dose at day eight.

Results show the change in average daily pain score as measured from baseline was greater with Vimpat given in the standard titration regimen than placebo. The change in pain score also was greater in the fast titration regimen than with placebo but did not reach statistical significance, according to UCB.